Drugs & Pharmaceuticals

Join Cameron English and  Dr. Chuck Dinerstein on Episode 97 of the Science Dispatch podcast as they discuss:

It's not easy being in pain these days. Tylenol is virtually useless, something you probably already know.

Zantac’s manufacturers were on a roll. Their defense had exacted a spate of favorable decisions and jury verdicts. Yet, on October 9, Glaxo Smith Kline (GSK) suddenly settled 93% of the remaining cases – for 2.2 billion dollars.

It was only a matter of time. It's not just our opioid laws that are a bona fide mess.

Join Cameron English and Dr. Chuck Dinerstein on Episode 95 of the Science Dispatch podcast as they discuss:

This may sound strange but on some level antiviral drug research is "easy." Make that "easy compared to other therapeutic areas," because those who do research in the antiviral field – something I did for 10 years – have an advantage over scientis

I will soon be writing about the possibility of the first-ever direct-acting antiviral drug (DAAD) for respiratory syncytial virus (RSV), courtesy of Enanta Pharmaceuticals, a Massachusetts biotech company spe

Drug Coverage’s Carrot and Stick

Spoiler alert (or savior alert, depending on how you look at it):

Join Cameron English and Dr. Chuck Dinerstein on Episode 90 of the Science Dispatch podcast as they discuss: